Adiponectin as a Target in Obesity-related Inflammatory State

Endocr Metab Immune Disord Drug Targets. 2015;15(2):145-50. doi: 10.2174/1871530315666150316122709.

Abstract

Accumulating evidence indicates that low grade inflammation is closely associated with obesity-related disorders including type 2 diabetes, hypertension and atherosclerosis. Adiponectin is a fat-derived plasma protein with anti-inflammatory functions. Circulating levels of adiponectin are decreased in obese states, and these conditions are broadly associated with various obesity-related diseases. Furthermore, adiponectin has direct protective functions against cardiovascular disease, cerebrovascular disease, non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD). In this review, we will focus on the protective functions of adiponectin against these obesity-related diseases from the view point of its anti-inflammatory properties.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adiponectin / metabolism*
  • Adiponectin / therapeutic use
  • Animals
  • Anti-Inflammatory Agents / therapeutic use
  • Cardiovascular Diseases / immunology
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / prevention & control
  • Drug Design
  • Humans
  • Inflammation / immunology
  • Inflammation / metabolism*
  • Inflammation / prevention & control
  • Insulin Resistance
  • Molecular Targeted Therapy
  • Non-alcoholic Fatty Liver Disease / immunology
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / prevention & control
  • Obesity / complications
  • Obesity / drug therapy
  • Obesity / immunology
  • Obesity / metabolism*
  • Protective Factors
  • Risk Factors
  • Signal Transduction

Substances

  • Adiponectin
  • Anti-Inflammatory Agents